The effect of thymic peptide combined with meropenem on patients with multidrug-resistant Klebsiella pneumoniae infection

doi:10.3760/cma.j.cn441417-20250122-21018

Abstract

Abstract:

Objective　To explore the effects of thymic peptide combined with meropenem on inflammatory cytokines and lymphocyte subpopulations in patients with multidrug-resistant Klebsiella pneumoniae infection. Methods　A retrospective analysis was conducted on 140 patients with multidrug-resistant Klebsiella pneumoniae infection who visited Henan Provincial Workers' Hospital from January 2023 to December 2024. Patients were randomly divided into a control group and an experimental group, with 70 cases in each group. The control group included 42 males and 28 females, with an average age of (55.99±7.51) years. The experimental group included 45 males and 25 females, with an average age of (57.02±6.96) years. The control group was given intravenous infusion of meropenem. The experimental group was treated with thymosin orally on the basis of the control group. Both groups received treatment for 7 days. Changes in inflammatory cytokines, lymphocyte subpopulations, clinical efficacy, and bacterial clearance rates were observed. Statistical analysis was conducted using χ² and t tests. Results　After treatment, the levels of interleukin (IL)-4, IL-6, tumor necrosis factor-alpha, IL-17A, and interferon-gamma in the experimental group were (9.12±1.81, 26.93±3.97, 12.96±1.38, 16.85±1.94, 17.82±2.66) ng/L, while in the control group they were (10.07±2.62, 30.72±5.36, 15.09±2.28, 19.82±2.19, 20.16±3.64) ng/L, with statistically significant differences (all P<0.05). The CD4⁺/CD8⁺ T lymphocyte ratio in the experimental group was higher than that in the control group (2.40±0.12 vs. 1.89±0.11, t=-26.210, P<0.001). The bacterial clearance rate and overall treatment efficacy in the experimental group were higher than those in the control group [78.57% (55/70) vs. 55.71% (39/70); 70.00% (49/70) vs. 48.57% (34/70)], with statistically significant differences (all P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (χ²=0.282, P=0.595). Conclusion　The combination of thymic peptide and meropenem in the treatment of multidrug-resistant Klebsiella pneumoniae can reduce levels of inflammatory cytokines, increase CD4⁺/CD8⁺ T lymphocyte subpopulations, and improve bacterial clearance rates and clinical efficacy, providing important guidance for the clinical treatment of multidrug-resistant Klebsiella pneumoniae.

Key words: Thymic peptide, Multidrug-resistant Klebsiella pneumoniae, Inflammatory cytokines, Lymphocytes

摘要： 目的　探讨胸腺肽联合美罗培南对多重耐药肺炎克雷伯菌感染患者炎症细胞因子及淋巴细胞亚群的影响。方法　回顾性分析2023年1月至2024年12月在河南省职工医院就诊的140例多重耐药肺炎克雷伯菌感染患者，按随机数字表法分为对照组和试验组，各70例。对照组男42例，女28例，年龄（55.99±7.51）岁。试验组男45例，女25例，年龄（57.02±6.96）岁。对照组给予美罗培南静脉滴注。试验组在对照组基础上联合使用胸腺肽口服。两组均连续用药7 d。比较两组炎症细胞因子、淋巴细胞亚群、细菌清除率、临床疗效、不良反应。采用χ²、t检验进行统计分析。结果　治疗后，试验组的白细胞介素（IL）-4、IL-6、肿瘤坏死因子-α分别为（9.12±1.81、26.93±3.97、12.96±1.38）ng/L，对照组分别为（10.07±2.62、30.72±5.36、15.09±2.28）ng/L，试验组的IL-17A、干扰素-γ水平均低于对照组，差异均有统计学意义（均P<0.05）；试验组的CD4⁺/CD8⁺ T淋巴细胞高于对照组（2.40±0.12比1.89±0.11，t=-26.210，P<0.001）；试验组的细菌清除率、治疗总有效率均高于对照组［78.57%（55/70）比55.71%（39/70）、70.00%（49/70）比48.57%（34/70）］，差异均有统计学意义（均P<0.05）。两组不良反应发生率差异无统计学意义（χ²=0.282，P=0.595）。结论　胸腺肽联合美罗培南治疗多重耐药肺炎克雷伯菌感染，可降低炎症细胞因子水平，提高CD4⁺/CD8⁺ T淋巴细胞亚群比值、细菌清除率及临床疗效，对多重耐药肺炎克雷伯菌感染的临床治疗具有重要指导意义。

关键词: 胸腺肽, 多重耐药肺炎克雷伯菌, 炎症细胞因子, 淋巴细胞

Xiao Huifang, Li Mingwei, Yuan Pujun, Feng Yulong, Lyu Xiliang, Wang Xiaobao. The effect of thymic peptide combined with meropenem on patients with multidrug-resistant Klebsiella pneumoniae infection[J]. International Medicine and Health Guidance News, 2025, 31(21): 3613-3617.

肖慧芳李明伟袁璞珺冯玉龙吕锡亮王小宝. 胸腺肽联合美罗培南治疗多重耐药肺炎克雷伯菌感染患者的疗效分析[J]. 国际医药卫生导报, 2025, 31(21): 3613-3617.

References

[1] Zhou Y, Wu C, Wang B, et al. Characterization difference of typical KL1, KL2 and ST11-KL64 hypervirulent and carbapenem-resistant Klebsiella pneumoniae[J]. Drug Resist Updat, 2023, 67:100918. DOI: 10.1016/j.drup.2023.100918.
[2] Gauba A, Rahman KM. Evaluation of antibiotic resistance mechanisms in Gram-negative bacteria[J]. Antibiotics (Basel), 2023,12(11):1590. DOI: 10.3390/antibiotics12111590.
[3] Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae[J]. Nat Rev Microbiol, 2020, 18(6):344-359. DOI: 10.1038/s41579-019-0315-1.
[4] Pu D, Zhao J, Chang K, et al. "Superbugs" with hypervirulence and carbapenem resistance in Klebsiella pneumoniae: the rise of such emerging nosocomial pathogens in China[J]. Sci Bull (Beijing), 2023, 68(21):2658-2670. DOI: 10.1016/j.scib.2023.09.040.
[5] Sha L, Zhang H, Zhang X. Thymic peptide α1 combined with XELOX improves immune function and reduces serum tumor markers in colorectal cancer patients after radical surgery[J]. Open Life Sci, 2024, 19(1):20220793. DOI: 10.1515/biol-2022-0793.
[6] Liu Q, Li L, Qin W, et al. Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors[J]. Cancer Biol Med, 2023, 20(11):856-868. DOI: 10.20892/j.issn.2095-3941.2023.0281.
[7] 李霞,张恩.重症监护病房老年患者多重耐药肺炎克雷伯菌感染危险因素分析[J].中国消毒学杂志, 2021, 38(5):3.DOI:10.11726/j.issn.1001-7658.2021.05.012.
[8] 韦华,鲁厚清,胡鑫.头孢哌酮舒巴坦钠联合替加环素治疗多重耐药肺炎克雷伯菌肺炎的临床研究[J].现代药物与临床,2023,38(12):3071-3075. DOI:10.7501/j.issn.1674-5515.2023.12.028
[9] 王小变.胸腺肽α1与头孢哌酮-舒巴坦钠对泛耐药鲍曼不动杆菌感染的重症肺炎患者的疗效及其对免疫功能改善的影响[J].抗感染药学,2021,18(1):141-144.DOI:10.13493/j.issn.1672-7878.2021.01-041.
[10] 李明伟,肖慧芳,冯玉龙. 凝血功能及机体免疫功能与肺炎严重程度的相关性分析[J]. 国际医药卫生导报,2023,29(15):2105-2109. DOI:10.3760/cma.j.issn.1007-1245.2023.15.008.
[11] 荣风燕,李金秀,张芸.血必净注射液联合头孢他啶治疗多重耐药肺炎克雷伯杆菌肺炎的临床研究[J].现代药物与临床,2024,39(7):1802-1807. DOI: 10.7501/j.issn.1674-5515.2024.07.020
[12] Zheng Z, Shao Z, Lu L, et al. Ceftazidime/avibactam combined with colistin: a novel attempt to treat carbapenem-resistant Gram-negative bacilli infection[J]. BMC Infect Dis, 2023, 23(1):709. DOI: 10.1186/s12879-023-08715-w.
[13] 于磊,李臻. 胸腺肽α1联合头孢哌酮—舒巴坦钠治疗对泛耐药鲍曼不动杆菌感染重症肺炎患者的效果分析[J]. 医学理论与实践,2023,36(13):2211-2213. DOI:10.19381/j.issn.1001-7585.2023.13.016.
[14] 杨媛,凌娜,唐朝政. 胸腺肽联合莫西沙星治疗老年慢性阻塞性肺疾病合并重症肺炎的效果[J]. 中国药物应用与监测,2024,21(4):328-331,380. DOI:10.3969/j.issn.1672-8157.2024.04.004.
[15] Wei Y, Zhang Y, Li P, et al. Thymic peptide α-1 in cancer therapy: Immunoregulation and potential applications[J]. Int Immunopharmacol, 2023, 117:109744. DOI: 10.1016/j.intimp.2023.109744.
[16] Liu K, Kong L, Cui H, et al. Thymic peptide α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy[J]. Cell Rep Med, 2024, 5(10):101751. DOI: 10.1016/j.xcrm.2024.101751.
[17] 王成娟,武光瑞.ICU高龄患者发生下呼吸道多重耐药肺炎克雷伯菌感染的病原学特点与影响因素分析[J].抗感染药学,2022,19(7):1055-1058,1088.DOI:10.13493/j.issn.1672-7878.2022.07-036.
[18] 刘正印. 合理使用抗菌药物,遏制细菌耐药[J/OL]. 中国医学前沿杂志(电子版),2017,9(4):10-12[2025-01-02]. https://d.wanfangdata.com.cn/periodical/ChVQZXJpb2RpY2FsQ0hJMjAyNTA2MjISEXpneXhxeXp6MjAxNzA0MDAzGghhanc2aHlvaA%3D%3D. DOI:10.12037/YXQY.2017.04-03.
[19] 杨启文,吴安华,胡必杰,等. 临床重要耐药菌感染传播防控策略专家共识[J]. 中国感染控制杂志,2021,20(1):1-14. DOI:10.12138/j.issn.1671-9638.20218124.
[20] Fernandez-Gonzalez A, Mukhia A, Nadkarni J, et al. Immunoregulatory macrophages modify local pulmonary immunity and ameliorate hypoxic pulmonary hypertension[J]. Arterioscler Thromb Vasc Biol, 2024,44(12):e288-e303. DOI: 10.1161/ATVBAHA.124.321264.
[21] 毛燕青,付婷,王娟,等. 老年多重耐药菌感染肺炎患者miR-127-5p、miR-127、miR-155表达水平及其与免疫相关细胞因子的相关性[J]. 实用医学杂志,2025,41(3):385-390. DOI:10.3969/j.issn.1006-5725.2025.03.012.
[22] 张昊,米婷,范亚莉,等. AECOPD患者T淋巴细胞亚群及血清CD64、TLR2与出院后再次发作的关系[J]. 国际医药卫生导报,2024,30(16):2696-2700. DOI:10.3760/cma.j.issn.1007-1245.2024.16.013.
[23] 刘璐,申潇竹,苗磊,等. 高龄社区获得性肺炎患者营养不良及调节性T细胞失衡与预后的相关性研究[J]. 国际医药卫生导报,2023,29(17):2413-2419. DOI:10.3760/cma.j.issn.1007-1245.2023.17.011.
[24] 许玲,季思勤,郑月娟,等. 金芪清疏方治疗肺脾气虚型社区获得性肺炎的临床疗效及对血清炎症因子和免疫功能的影响[J]. 河北中医,2025,47(1):20-25. DOI:10.3969/j.issn.1002-2619.2025.01.005.
[25] 游翔,黄小婷,吴朝晖,等. 头孢他啶阿维巴坦治疗碳青霉烯类耐药革兰氏阴性菌感染患者的真实世界研究[J]. 中国医院药学杂志,2025,45(2):203-208. DOI:10.13286/j.1001-5213.2025.02.13.
[26] Yang M, Wang B. A case report of invasive klebsiella pneumoniae liver abscess syndrome treated with ceftazidime-avibactam in combination with meropenem[J]. Infect Drug Resist, 2024, 17:4161-4165. DOI: 10.2147/IDR.S480665.